MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to companies across all industries. We provide a broad array of products intended to finance growth and manage working capital. As of January 2015, MidCap Financial has over $3 billion of commitments under management. Since our founding in 2008, we have been working with management teams and sponsors to deliver thoughtful and cost effective debt solutions. Companies need a lender that understands their business and has the creativity and flexibility to provide financing solutions that are suited to their needs. At MidCap Financial, our years of experience, strong balance sheet, and flexibility make us the lender of choice for companies across all stages of growth and complexity. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management agreement. Apollo Global Management is one of the world's largest asset managers with over $160B of assets under management (as of January 2015), providing market leading industry expertise, market reach, and financing synergies.
Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data, AI, and machine-to-machine communication.
Arq
Post in 2024
Arq is an environmental technology company that focuses on transforming mining waste into high-value advanced carbon products. By leveraging innovative technologies, Arq aims to contribute to a cleaner and safer world while actively reducing its environmental footprint. The company's operations emphasize sustainability and resource recovery, positioning it as a key player in the oil and energy sector. Through its commitment to environmental responsibility, Arq strives to create solutions that not only enhance the value of mining byproducts but also promote a more sustainable future.
Regis Corporation
Post in 2024
Regis Corporation is a prominent owner, operator, and franchisor of hairstyling and hair care salons, headquartered in Minneapolis, Minnesota. The company operates in the United States, the United Kingdom, Canada, and Puerto Rico, managing over 8,600 salons across various brands, including SmartStyle, Supercuts, Cost Cutters, Roosters, and First Choice Haircutters. Regis provides a range of services such as haircutting, styling, hair coloring, and other beauty treatments, along with the sale of hair care products. In addition to salon services, the company offers digital solutions like OpenSalon Pro, a cloud-based salon management system, and mobile applications for booking and check-in services. Founded in 1922, Regis also operates accredited cosmetology schools and employs more than 41,000 individuals worldwide.
Xtant Medical
Post in 2024
Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.
OrthoPediatrics
Post in 2024
OrthoPediatrics is a medical device company focused on the pediatric orthopedic market, dedicated to improving the treatment of children's orthopedic conditions. The company designs, develops, and manufactures a range of orthopedic implants and instruments tailored specifically for pediatric orthopedic surgeons and small stature patients. Its product lineup includes innovative offerings such as PediLoc, PediPlates, Cannulated Screws, PediFlex nail, and the PediNail, among others. OrthoPediatrics aims to enhance surgical outcomes by providing anatomically appropriate solutions that address the unique needs of its patients, thereby advancing the field of pediatric orthopedics. The company also emphasizes the importance of reducing anxiety during procedures, as demonstrated by its QCR technology, which operates quietly and minimizes vibration while effectively cutting through casting materials.
Express Wash Concepts
Debt Financing in 2023
Express Wash Concepts operates a chain of car washing facilities dedicated to delivering exceptional customer service and high-quality vehicle cleaning experiences. The company focuses on providing comprehensive maintenance and cleaning services for vehicle owners, specializing in car washing and vacuum cleaning. By prioritizing customer satisfaction, Express Wash Concepts aims to create a reliable and efficient environment for customers to care for their vehicles.
STRATA Skin Sciences
Post in 2023
STRATA Skin Sciences, Inc. is a medical technology company focused on developing and marketing products for dermatological conditions in the United States and Asia. The company operates two main segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its key products include the XTRAC excimer laser and VTRAC lamp systems, which are designed to treat skin disorders such as psoriasis, vitiligo, atopic dermatitis, and eczema. Additionally, STRATA offers the MelaFind system to aid in the identification and management of melanoma skin cancer. The company distributes its products both internationally through distributors and domestically directly to physicians. Founded in 1989, STRATA Skin Sciences is headquartered in Horsham, Pennsylvania.
Marco
Debt Financing in 2023
Marco is a tech-enabled, trade finance platform that provides reliable access to working capital for Latin American SMEs. It promotes paperless processes and dedicated support from industry experts to create a seamless financing solution. The company was founded in 2019 by Jacob Shoihet and Peter D. Spradling and is headquartered in Miami, Florida.
Apyx Medical
Post in 2023
Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.
ViewRay
Post in 2022
ViewRay, Inc. is a company that designs, manufactures, and markets advanced radiation therapy systems for cancer treatment. Its primary product, MRIdian, is an MRI-guided radiation therapy system that allows for simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology, radiation delivery, and proprietary software to accurately locate and track soft-tissue tumors, enabling precise targeting while minimizing radiation exposure to surrounding healthy tissues. By providing real-time imaging during treatment, MRIdian addresses significant limitations of traditional radiation therapy methods, enhancing the safety and effectiveness of cancer treatment. ViewRay serves a diverse clientele, including university hospitals, community hospitals, private practices, government institutions, and independent cancer centers, primarily in the United States and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Surmodics
Post in 2022
Surmodics is a healthcare company specializing in surface modification and in vitro diagnostic technologies. It aims to enhance disease treatment and detection through innovative solutions that address complex medical device and diagnostic challenges. The company operates in two main segments: the medical device unit, which focuses on developing differentiated vascular intervention devices and performance coatings, and the in vitro diagnostics unit, which manufactures chemical and biological components for immunoassays and molecular tests used in diagnostic and biomedical research. Surmodics leverages its expertise in proprietary surface modification and drug-delivery coating technologies alongside its capabilities in device design, development, and manufacturing to meet demanding clinical requirements and support the healthcare industry.
Carbon6
Debt Financing in 2022
Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.
Carbon6
Series A in 2022
Carbon6 provides a comprehensive suite of software tools designed to enhance the performance of eCommerce businesses on Amazon. The platform offers solutions for listing optimization, profit recovery, PPC management, and inventory control, enabling sellers to drive revenue and operate efficiently. Carbon6 aims to support brand owners and operators in achieving their business goals through innovative technology and data-driven insights.
TELA Bio
Post in 2022
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.
Forge Biologics
Debt Financing in 2022
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.
Aterian
Post in 2021
Aterian is a technology-driven consumer products company that specializes in building, acquiring, and partnering with various brands. Founded in 2014, Aterian operates a diverse range of product categories, including home and kitchen appliances, kitchenware, environmental appliances, beauty products, and consumer electronics. The company utilizes proprietary software and an agile supply chain to efficiently create and market top-selling consumer products. Aterian manages several owned brands, such as Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. With a global presence that includes offices in America, Canada, Poland, Israel, China, and the Philippines, as well as remote employees in France, Australia, and Croatia, Aterian focuses on generating revenue primarily through online sales of its various consumer products.
UpStack
Debt Financing in 2021
UpStack is a company that specializes in providing customized cloud infrastructure solutions through its innovative SaaS-based colocation procurement platform. The platform aids businesses in making informed decisions by utilizing pricing normalization technology, which equalizes pricing across various data center vendors. This approach eliminates guesswork and errors, allowing IT professionals, systems integrators, and consultants to efficiently discover, price, and procure colocation services. By streamlining the procurement process, UpStack significantly reduces both the time and costs typically associated with traditional methods, making it easier for businesses of all sizes to navigate their infrastructure challenges.
Unchained Labs
Debt Financing in 2021
Unchained Labs is a developer of life science biologics tools designed to help researchers break free from tools that just don't cut it. It offers a multiplex protein stability platform for biologics that measures a host of protein stability parameters. The company's products include protein sizing systems, stability quantifiers, benchtop workflow solutions, automated buffer exchanges, concentration liberators, particle identifiers, and more, enabling biologics researchers to speed up their work with ease. Unchained Labs was established in 2013 and is based in Pleasanton, California, USA.
Modern Campus
Debt Financing in 2021
Modern Campus is a software company specializing in student lifecycle management solutions tailored for higher education institutions. Its SaaS platform focuses on managing continuing education and non-degree programs, catering to students outside the traditional full-time degree framework. By enhancing digital engagement, Modern Campus aims to improve the overall student experience, enabling institutions to increase enrollment, streamline administrative processes, and efficiently oversee their educational offerings.
Xtant Medical
Post in 2021
Xtant Medical is a medical technology company that specializes in the design, development, and commercialization of regenerative medicine products and medical devices, particularly in the orthopedic and neurosurgery markets. The company offers a comprehensive portfolio of orthobiologics and spinal implant systems designed to facilitate spinal fusion in complex procedures. Its product lineup includes biomaterials such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and 3Demin products, along with various allografts. Xtant Medical primarily serves orthopedic spine surgeons and neurosurgeons treating a range of spinal disorders across different anatomical regions. With a strong presence in the United States, the company has a large field sales force and numerous national and regional contracts, enhancing its competitive position in the spine surgery marketplace. The merger of Bacterin International and X-spine Systems has further strengthened Xtant Medical's product offerings and market reach, promoting growth and innovation in the field.
LendingPoint
Debt Financing in 2021
LendingPoint LLC is a financial technology company based in Kennesaw, Georgia, with additional offices in New York and Nevada. Founded in 2014, it specializes in providing online consumer loans through a cloud-based lending platform that employs predictive risk algorithms. LendingPoint offers personal loans for various purposes, including debt consolidation, home improvement, credit card refinancing, and medical expenses. Additionally, the company operates LendingPoint Merchant Solutions, which provides financing options for merchants, service providers, and medical institutions. The firm's services extend to e-commerce and point-of-sale financing, leveraging advanced fraud prevention and risk management strategies to create financing opportunities across the credit spectrum.
Medexus Pharmaceuticals
Debt Financing in 2020
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.
Digital Reasoning
Series D in 2020
Digital Reasoning Systems, Inc. specializes in developing artificial intelligence solutions that automate the analysis and organization of unstructured data for businesses. Founded in 2000 and headquartered in Franklin, Tennessee, the company offers its flagship product, Synthesys, which utilizes advanced features such as natural language processing and entity resolution to categorize and link data effectively. This platform is designed to provide critical insights and intelligence for various sectors, including government, finance, healthcare, and legal markets. Digital Reasoning’s solutions help clients visualize connections within data sets, enhancing their ability to identify risks and threats. The company also maintains strategic partnerships to expand its offerings and reach. Additional offices are located in New York, Washington, D.C., and London.
Arboretum Investment Advisors, LLC.
Debt Financing in 2019
Arboretum provides financing for fundamental capital assets which are business essential to middle market companies worldwide.
Protagonist Therapeutics
Post in 2019
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on developing peptide-based product candidates to meet unmet medical needs in hematology and gastroenterology. The company is advancing several key products, including PTG-300, an injectable hepcidin mimetic in Phase II clinical trials for treating beta-thalassemia-related anemia, and PTG-200, an antagonist peptide that has completed Phase I trials aimed at moderate-to-severe Crohn's disease. Additionally, PN-943, an oral integrin antagonist, is in Phase I trials for inflammatory bowel disease. Protagonist also explores both oral and injectable peptide candidates for various gastrointestinal conditions. The company has established a collaboration with Janssen Biotech for the development and commercialization of PTG-200. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California.
Sight Sciences
Series D in 2019
Sight Sciences is a medical device company specializing in ophthalmic devices and glaucoma implants aimed at treating irreversible blindness. Headquartered in Menlo Park, California, the company has developed the OMNI Surgical System, which allows for targeted treatment of glaucoma by addressing three points of resistance with a single device and incision. Additionally, Sight Sciences offers TearCare, a wearable technology that delivers adjustable thermal energy to the meibomian glands to treat conditions like dry eye and meibomian gland dysfunction. The company also provides SmartLid, which aids in the natural expression of meibum when it is in a melted state. Founded in 2010, Sight Sciences focuses on both surgical and non-surgical technologies to address prevalent eye diseases and has a commercial office in Southlake, Texas.
Gossamer Bio
Post in 2019
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.
Sonar Entertainment
Debt Financing in 2018
Sonar Entertainment, Inc. is an independent entertainment studio based in Los Angeles, California, with additional offices in Toronto, Miami, London, Sydney, and Singapore. Founded in 1979 and formerly known as RHI Entertainment, the company specializes in the development, production, financing, and distribution of television series, miniseries, and movies for both domestic and international audiences. Sonar offers a diverse range of content across various genres, including action, comedy, drama, horror, and reality. It also distributes a library of titles and sells DVDs and digital media products online. With a commitment to nurturing creative talent, Sonar provides a comprehensive platform that supports the entire production process while ensuring broad access to its content through collaborations with local networks and producers.
Kashable
Debt Financing in 2018
Kashable LLC operates an online platform that provides employer-sponsored voluntary benefit programs, focusing on financial wellness for employees. Founded in 2013 and based in New York, the company allows eligible employees to apply for loans online, facilitating access to affordable financing for managing debt or covering unexpected expenses. The platform enables automatic repayment through structured payroll deductions, ensuring a seamless experience for users. By offering socially responsible financing options, Kashable aims to support employees in achieving better financial stability while providing employers with a valuable benefit to enhance their employee assistance programs.
The Credit Junction
Debt Financing in 2018
The Credit Junction is the first data-driven asset-based lending platform and is transforming the way small and mid-size businesses access working capital, growth, and supply chain financing solutions. The company combines technology and data intelligence with traditional asset-based credit metrics and offers up to $7.5 million in capital availability. The Credit Junction targets growth-oriented suppliers, distributors, and manufacturers typically with revenues between $5M and $50M. It was founded in 2014 and is headquartered in New York, United States.
ZPower
Debt Financing in 2018
ZPower, LLC is a developer and manufacturer of rechargeable silver-zinc micro batteries, primarily serving the hearing aid, medical device, and portable electronics markets. Founded in 1996 and based in Camarillo, California, the company offers a range of products, including various models of rechargeable micro batteries and charging systems for hearing aids. ZPower's advanced battery technology aims to enhance product development for manufacturers and improve performance for end-users, promoting a better user experience and environmental sustainability. The company filed for reorganization under Chapter 11 in March 2020, indicating ongoing challenges in its operations.
Partner Therapeutics
Series A in 2018
Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, dedicated to the development and commercialization of approved and late-stage cancer therapies. The company focuses on improving treatment outcomes and reducing overall healthcare costs for cancer patients through a comprehensive range of therapies, from primary treatments to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells to aid in cancer treatment. Founded in 2017, Partner Therapeutics aims to connect investigators and healthcare professionals in the field of oncology, ensuring effective treatments are accessible to patients at all stages of their cancer journey.
Fundation
Debt Financing in 2017
Fundation is a technology-driven company focused on enhancing the credit delivery process for small and medium-sized businesses (SMBs). By combining financial services expertise with modern digital technology, Fundation has developed a digital account origination and insights platform that simplifies the borrowing and account opening experience for SMBs. This platform streamlines loan and deposit origination workflows for various products, including business loans, lines of credit, and checking accounts. Fundation partners with a range of financial institutions, from community banks to B2B vendors, to empower them in serving their small business clients more effectively. The company's mission is to support the small business economy by providing innovative solutions that improve the overall experience for both lenders and borrowers.
Oxford Immunotec
Post in 2016
Oxford Immunotec is a medical diagnostics company specializing in the development of novel tests for various diseases through its patented T cell measurement technology. The company has pioneered the T-SPOT.TB test, an interferon gamma release assay designed to diagnose latent tuberculosis infection and active TB disease, serving as a modern alternative to the traditional Mantoux skin test. In addition to its focus on tuberculosis, Oxford Immunotec is dedicated to advancing proprietary diagnostic tests for a range of underserved immune-regulated conditions, including chronic infections, transplantation, autoimmune and inflammatory diseases, and immune oncology. Through its innovative approach, the company aims to enhance the management of these conditions and improve patient outcomes.
Intarcia Therapeutics
Debt Financing in 2016
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.
IOU Financial
Post in 2016
Having funded over $200 million is small business loans; IOU Financial has the experience to help any business get what they need. They have offices all over the world and the knowledge and flexibility to get your business the capital it needs to seize the growth opportunities that will help you realize their potential
Spectra7 Microsystems
Post in 2016
Spectra7 Microsystems is a semiconductor company delivering unprecedented bandwidth, speed, and resolution to enable disruptive industrial design for leading consumer electronics manufacturers in virtual reality, augmented reality, data centers, and other connectivity markets. It specializes in the fields of wireless infrastructure and data center active cables.
The Spectranetics
Post in 2015
Spectranetics is a medical technology company based in Colorado that specializes in developing single-use tools for minimally invasive cardiovascular surgeries. The company focuses on lead management, as well as peripheral and coronary interventions, offering advanced products such as scoring balloon technology and laser atherectomy. Spectranetics provides healthcare providers with innovative solutions and proven algorithms to effectively manage cardiac leads, modify plaque, and address complications like restenosis and amputation. With a commitment to product innovation, Spectranetics continually explores new methods to enhance the effectiveness and efficiency of complex cardiovascular procedures, ultimately aiming to improve patient outcomes and quality of life.
Flexion Therapeutics
Post in 2015
Flexion Therapeutics, Inc. is a biopharmaceutical company based in Burlington, Massachusetts, dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions, particularly osteoarthritis. The company offers ZILRETTA, an intra-articular injection designed to manage knee pain associated with osteoarthritis in the United States. Additionally, Flexion is developing FX201, a gene therapy aimed at stimulating the production of an anti-inflammatory protein to provide pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Founded in 2007, Flexion Therapeutics collaborates with pharmaceutical and biotechnology companies to advance its drug candidates through clinical proof of concept and beyond, thereby enhancing their partners' portfolios while sharing expertise and risk.
Quotient Biodiagnostics
Post in 2015
Quotient Biodiagnostics is focused on providing high quality, high value immunohematology products to hospitals and blood banks in the US. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies.
Staffing 360 Solutions
Post in 2015
Staffing 360 Solutions is a company operating in the international staffing sector, focusing on professional placement and staffing services across various industries. It employs a buy-and-build strategy by acquiring both domestic and international staffing organizations. The company is organized into three business streams: Professional Staffing, Commercial Staffing, and Employer of Record. Staffing 360 Solutions primarily supports sectors such as accounting and finance, information technology, engineering, administration, and commercial disciplines. By integrating acquired firms, the company aims to enhance its service offerings and expand its market presence globally.
Aventine Renewable Energy Holdings
Debt Financing in 2014
Aventine Renewable Energy Holdings is a prominent producer of corn-based fuel-grade ethanol and related by-products. The company specializes in the production and marketing of renewable fuels, which serve as gasoline additives and contribute to reducing dependence on foreign oil. Aventine's facilities focus on generating low carbon renewable fuels, including ethanol and various co-products, which also help offset a substantial portion of corn costs. By supplying these products to major energy and food companies in the United States and globally, Aventine plays a significant role in promoting environmental sustainability and improving automobile performance.
Larimar Therapeutics
Debt Financing in 2014
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.
Omeros
Post in 2014
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.
Amicus Therapeutics
Post in 2013
Amicus Therapeutics is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. The company is known for its product Galafold, an orally administered small molecule pharmacological chaperone specifically designed for treating Fabry disease. Amicus is also advancing its clinical pipeline, including a Phase 3 study of AT-GAA for Pompe disease. The company focuses on creating novel therapies, particularly pharmacological chaperones, which are intended to stabilize and enhance the activity of misfolded enzymes in patients. This approach may improve treatment outcomes, especially when used in conjunction with enzyme replacement therapy. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey, collaborating with institutions like Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.
Apollo Endosurgery
Debt Financing in 2013
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, that specializes in the design, development, and commercialization of devices for gastrointestinal therapeutic endoscopy. Founded in 2005, the company offers a range of innovative products aimed at reducing the need for invasive surgical procedures. Key offerings include the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which allow physicians to place full-thickness sutures through a flexible endoscope, and the X-Tack Endoscopic HeliX Tacking System. Additionally, Apollo provides the Orbera Intragastric Balloon, which helps manage obesity by reducing stomach capacity. The company's solutions are designed to lower complication rates and overall healthcare costs, making them valuable tools for gastroenterologists and bariatric surgeons. Apollo Endosurgery distributes its products to medical service providers, hospitals, outpatient surgical centers, clinics, and physicians across the United States, Brazil, Australia, and various European countries.
Quotient Biodiagnostics
Debt Financing in 2013
Quotient Biodiagnostics is focused on providing high quality, high value immunohematology products to hospitals and blood banks in the US. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers more than 30 years of research, development and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies.
Theraclone Sciences
Debt Financing in 2013
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Stellar Pharmaceuticals
Debt Financing in 2012
Stellar Pharmaceuticals Inc. is an innovative Canadian Health Care Company focused on providing healthcare professionals and their patients.
Endocyte
Venture Round in 2010
Endocyte, Inc. is a biopharmaceutical company focused on developing receptor-targeted therapies for cancer and inflammatory diseases. Headquartered in West Lafayette, Indiana, the company creates innovative small molecule drug conjugates (SMDCs) and companion imaging agents. Among its key products, Vintafolide is in Phase IIb clinical trials for non-small cell lung cancer, while EC1456 and EC1169 are in Phase I trials for advanced solid tumors and metastatic castration-resistant prostate cancer, respectively. Additionally, Endocyte is developing several pre-clinical candidates, including EC2629 for cancer treatment and EC2319 for inflammatory diseases. The company has established collaborations with Purdue Research Foundation and other organizations to advance its pipeline. Founded in 1995, Endocyte operates as a subsidiary of Novartis AG.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.